FDA advisory committee recommends black box warning for ADHD drugs


    loading  Checking for direct PDF access through Ovid

Abstract

précisNew recommendation from the FDA's Drug Safety and Risk Management Advisory Committee calls for a black box warning for ADHD drugsNew warnings could caution patients and prescribers of possible increased risk of serious cardiovascular events in children and adultsThe recommendation appears to be controversial, with the FDA, APA, AACAP and other organizations calling for additional research before mandating a warningBottom line: continue to follow the advice on the current ADHD drug labels and stay abreast of new research and FDA announcements

    loading  Loading Related Articles